Nurix Reports Positive Results For BTK Degrader NX-5948 In Waldenstrom’s Macroglobulinemia
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Nurix Therapeutics Inc. (NRIX) presented positive clinical data from its ongoing Phase 1a/1b clinical trial of NX-5948, an orally bioavailable, brain-penetrant degrader of Burton’s tyrosine kinase or BTK, in patients with relapsed/refractory Waldenström’s macroglobuli
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1803777103-b9626d35c9fd4424ae7ecc3b6d58a558.jpg "Accountant Career Path and Qualifications")
:max_bytes(150000):strip_icc():format(jpeg)/AFFLUENT.MILLENNIAL.HERO.GettyImages-868506558_2600-84706e45802340b1865d4b49c285a662.jpg "The Affluent Millennial Investing Survey")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2151279555-f38549a64433496982ff93944b309afb.jpg "5 Transamerica Mutual Funds to Consider")
